A phase 2 study of VALO-D102 in Europe
Latest Information Update: 14 Jan 2023
At a glance
- Drugs VALO-D102 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
Most Recent Events
- 14 Jan 2023 New trial record
- 11 Jan 2023 According to a Valo Therapeutics media release, the company plans to has selected Exothera to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102. Exothera will perform tech transfer, analytical development, and scale-up to initiate manufacturing of clinical material for this study.